Core Viewpoint - Shenzhen Zhaojixin Biotech Co., Ltd. has completed a seed round financing of several tens of millions, aimed at accelerating the development and industrialization of its AI-driven high-throughput, ultra-sensitive proteomics bioanalysis platform [1] Group 1: Financing Details - The financing round was led by Shenzhen Capital Group's seed fund, with participation from Nanshan Innovation Investment and Guangming Tainuo Seed Fund [1] - The funds will primarily be used to advance the research and industrialization processes of the company's bioanalysis platform, as well as to expand its team and technology layout in drug development and clinical diagnostics [1] Group 2: Company Overview - Zhaojixin was established in June 2023 and focuses on integrating advanced semiconductor technology with artificial intelligence in the field of bioanalysis [1] - The company aims to develop a next-generation ultra-sensitive proteomics platform that provides efficient, precise, and cost-effective intelligent solutions for upstream life sciences research, new drug development, and clinical diagnostics [1] - The core objective is to facilitate a transition in protein detection technology from traditional optical methods to semiconductor digitalization and AI intelligence [1] Group 3: Leadership and Ownership - The actual controller of Zhaojixin is Zhang Qingyang, who holds a total shareholding ratio of 49.12% and a voting power of 50.86% [1] - Zhang Qingyang currently serves as the chairman and manager of the company [1]